Analytical Data
-
基因名
PAFAH1B3
- Application
-
别名
PAFAH1B3;PAFAHG;Platelet-activating factor acetylhydrolase IB subunit alpha1
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q15102
-
表达区间
1-231aa
-
氨基酸序列
MGSSHHHHHH SSGLVPRGSH MGSMSGEENP ASKPTPVQDV QGDGRWMSLH HRFVADSKDK EPEVVFIGDS LVQLMHQCEI WRELFSPLHA LNFGIGGDGT QHVLWRLENG ELEHIRPKIV VVWVGTNNHG HTAEQVTGGI KAIVQLVNER QPQARVVVLG LLPRGQHPNP LREKNRQVNE LVRAALAGHP RAHFLDADPG FVHSDGTISH HDMYDYLHLS RLGYTPVCRA LHSLLLRLLA QDQGQGAPLL EPAP
-
分子量
28 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PAFAH1B3, also known as platelet-activating factor acetylhydrolase 1b catalytic subunit 3, is a vital enzyme involved in lipid metabolism and inflammatory responses. Its primary function is to hydrolyze platelet-activating factor (PAF), a potent phospholipid mediator that plays a crucial role in various physiological processes, including immune response and inflammation. The study of PAFAH1B3 is significant due to its implications in several disease states, such as cardiovascular diseases, neurodegenerative disorders, and various inflammatory conditions. Research has indicated that dysregulation of PAFAH1B3 activity can lead to altered PAF levels, contributing to pathophysiological conditions. Furthermore, PAFAH1B3 has been identified as a potential therapeutic target, making it a subject of interest for drug development. The recombinant protein version of PAFAH1B3 allows for detailed studies of its enzymatic activity, interaction with substrates, and potential inhibitors. This not only aids in understanding its biological roles but also facilitates the exploration of clinical applications in modulating inflammatory responses and treating related diseases. As such, research on PAFAH1B3 and its recombinant forms has become increasingly relevant in the realms of biochemistry, pharmacology, and therapeutic development, potentially leading to innovative strategies for managing health conditions related to its dysregulation.
